Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1991 2
1992 2
1994 2
1998 1
1999 2
2000 1
2004 2
2005 1
2007 1
2008 1
2009 2
2010 2
2011 3
2012 2
2013 3
2015 4
2016 4
2017 9
2018 15
2019 13
2020 17
2021 16
2022 13
2023 7
2024 5
2025 7
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
Ebata S, Yoshizaki A, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Okiyama N, Kodera M, Hasegawa M, Sato S. Ebata S, et al. Lancet Rheumatol. 2022 Aug;4(8):e546-e555. doi: 10.1016/S2665-9913(22)00131-X. Epub 2022 Jun 28. Lancet Rheumatol. 2022. PMID: 38294008 Clinical Trial.
Involvement of B cells in the development of systemic sclerosis.
Yoshizaki A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Sato S. Yoshizaki A, et al. Among authors: ebata s. Front Immunol. 2022 Jul 28;13:938785. doi: 10.3389/fimmu.2022.938785. eCollection 2022. Front Immunol. 2022. PMID: 35967355 Free PMC article. Review.
Predictors of rituximab efficacy in systemic sclerosis-associated interstitial lung disease: machine-learning analysis of the DESIRES trial.
Kuzumi A, Oba K, Ebata S, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Kage H, Sato S, Yoshizaki A. Kuzumi A, et al. Among authors: ebata s. Rheumatology (Oxford). 2025 Dec 1;64(SI):SI114-SI121. doi: 10.1093/rheumatology/keae716. Rheumatology (Oxford). 2025. PMID: 39718799 Free PMC article. Clinical Trial.
Japanese Orthopaedic Association (JOA) clinical practice guidelines on the management of lumbar disc herniation, third edition - secondary publication.
Haro H, Ebata S, Inoue G, Kaito T, Komori H, Ohba T, Sakai D, Sakai T, Seki S, Shiga Y, Suzuki H, Toyota H, Watanabe K, Yamato Y. Haro H, et al. Among authors: ebata s. J Orthop Sci. 2022 Jan;27(1):31-78. doi: 10.1016/j.jos.2021.07.028. Epub 2021 Dec 2. J Orthop Sci. 2022. PMID: 34865915 Review. No abstract available.
121 results